Letter of Answering Reviewers

Dear reviewers:

First of all, thank you very much for your valuable suggestions. We have made several revisions to our manuscript according to your comments. They are listed as follows:

1. A more thorough description of the patient's history of present illness was added including multiple conventional therapies used before adalimumab and vedolizumab. The reasons why adalimumab was initially administered and then switched to vedolizumab were explained (due to the failure of conventional therapy and severely continued symptoms, e.g. 10 to 20 bowel movements daily).

2. The Naranjo adverse drug reaction (ADR) scale was calculated to be 6 (+1 for previous conclusive reports on this reaction; +1 for the ADR improved after the discontinuation of the first dose of the drug; +2 for ADR appear after the suspected drug; +2 for the ADR reappear when the drug was administered; -1 for there are alternative causes for this ADR; +1 for the ADR was confirmed by objective evidence). The Naranjo score was not evaluated before the second dose of vedolizumab.

Again, thank you very much for your valued reviews.

Sincerely yours,

Chang Dong, MD, Associate Chief Physician, Associate Professor
First Affiliated Hospital of Dalian Medical University
No. 222 Zhongshan Road, Xigang District, Dalian 116011, China
Email: dongchang8793@163.com